States Offering Broad GLP-1 Coverage for Obesity A total of 14 states, including California, Michigan, and Pennsylvania, provide Medicaid coverage for the most common GLP-1s approved for both Type 2 diabetes and obesity
What have been the results of the Mounjaro clinical trials
A recent large-scale clinical trial has confirmed that tirzepatide, a dual GIP and GLP-1RAs, resulted in a weight loss of up to 20.9% in adults with body fat mass of 30 or more after 72-week follow-up [22]
It may not be as effective for some conditions as many supplement companies claim
Using these alone (without diet and exercise) is unlikely to make any difference
Furthermore, such heterotypic interactions do not necessitate classical -sheet-rich amyloid fibril formation, but rather favor amorphous, lipidrich, and membranedense inclusions